非格司亭

非格司亭(Filgrastim)是一種治療嗜中性白血球低下的藥物[21]。造成嗜中性白血球低下的病因包括:愛滋病患者、化學療法放射治療後,或原因不明[21]。也可以用進行白血球分離術英語Leukapheresis前,先用此藥可以增加白血球的數量,增加效率[21]。可靜脈注射皮下注射給藥[21]

非格司亭
臨床資料
商品名英語Drug nomenclatureNeupogen, others
其他名稱XM02
生物相似藥filgrastim-aafi,[1] filgrastim-ayow,[2] filgrastim-sndz, filgrastim-txid[3] Accofil,[4] Biograstim,[5] Fraven, Grastofil,[6] Nivestim,[7] Nivestym,[8] Nypozi,[3][9] Ratiograstim,[10][11] Releuko,[2] Tevagrastim, Zarxio,[12][13] Zarzio[14]
AHFS/Drugs.comMonograph
MedlinePlusa692033
核准狀況
懷孕分級
給藥途徑靜脈注射皮下注射
藥物類別英語Drug class造血因子、集落刺激因子
ATC碼
法律規範狀態
法律規範
識別資訊
  • Human granulocyte colony stimulating factor
CAS號121181-53-1
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
ECHA InfoCard100.167.401 編輯維基數據鏈接
化學資訊
化學式C845H1343N223O243S9
摩爾質量18,802.90 g·mol−1

常見副作用包括發燒、咳嗽、胸痛、關節痛、嘔吐和脫髮[21]。嚴重副作用包括脾臟受傷英語Splenic injury過敏[21]懷孕期使用對胎兒的安全仍不清楚[21]。非格司亭是天然存在的白血球生長激素英語Granulocyte colony-stimulating factor,以重組 DNA 方式製造[21]。它會刺激身體增加中性粒細胞的數量[21]

非格司亭於 1991 年在美國取得醫療使用許可[21]。名列世界衛生組織基本藥物標準清單[22]。在美國,已有生物仿製[21]

參考文獻

  1. ^ Drug Approval Package: Nivestym (filgrastim-aafi). U.S. Food and Drug Administration (FDA). 21 February 2019 [20 December 2019]. (原始內容存檔於20 December 2019). 
  2. ^ 2.0 2.1 Releuko- filgrastim injection, solution. DailyMed. 11 March 2022 [16 March 2022]. (原始內容存檔於17 March 2022). 
  3. ^ 3.0 3.1 https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761126s000lbl.pdf [裸網址]
  4. ^ Accofil EPAR. European Medicines Agency (EMA). 17 September 2018 [2 April 2020]. (原始內容存檔於23 March 2020). 
  5. ^ Biograstim EPAR. European Medicines Agency (EMA). 17 September 2018 [2 April 2020]. (原始內容存檔於22 October 2020). 
  6. ^ Grastofil EPAR. European Medicines Agency (EMA). 17 September 2018 [2 April 2020]. (原始內容存檔於12 November 2020). 
  7. ^ 7.0 7.1 Nivestim EPAR. European Medicines Agency (EMA). 17 September 2018 [20 December 2019]. (原始內容存檔於20 December 2019). 
  8. ^ Summary Basis of Decision (SBD) for Nivestym. Health Canada. 23 October 2014 [29 May 2022]. (原始內容存檔於30 May 2022). 
  9. ^ Summary Basis of Decision (SBD) for Nypozi. Health Canada. 23 October 2014 [29 May 2022]. (原始內容存檔於25 September 2022). 
  10. ^ Ratiograstim EPAR. European Medicines Agency (EMA). 17 September 2018 [2 April 2020]. (原始內容存檔於14 August 2020). 
  11. ^ Tevagrastim EPAR. European Medicines Agency (EMA). 17 September 2018 [2 April 2020]. (原始內容存檔於16 October 2019). 
  12. ^ FDA approves first biosimilar product Zarxio. U.S. Food and Drug Administration (FDA) (新聞稿). 6 March 2015 [23 November 2015]. (原始內容存檔於11 December 2015). 
  13. ^ Zarxio (filgrastim-sndz). U.S. Food and Drug Administration (FDA). 20 April 2015 [20 December 2019]. (原始內容存檔於20 December 2019). 
  14. ^ Zarzio EPAR. European Medicines Agency (EMA). 17 September 2018 [20 December 2019]. (原始內容存檔於15 October 2019). 
  15. ^ Filgrastim Use During Pregnancy. Drugs.com. 13 September 2018 [17 December 2019]. (原始內容存檔於18 December 2019). 
  16. ^ Health product highlights 2021: Annexes of products approved in 2021. Health Canada. 3 August 2022 [25 March 2024]. 
  17. ^ Neupogen 30 MU (0.3 mg/ml) solution for injection - Summary of Product Characteristics (SmPC). (emc). 7 May 2021 [1 March 2022]. (原始內容存檔於1 March 2022). 
  18. ^ Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe - Summary of Product Characteristics (SmPC). (emc). 4 July 2019 [20 December 2019]. (原始內容存檔於20 December 2019). 
  19. ^ Nivestim 12 MU/ 0.2 ml solution for injection/infusion - Summary of Product Characteristics (SmPC). (emc). 18 December 2019 [20 December 2019]. (原始內容存檔於20 December 2019). 
  20. ^ Neupogen- filgrastim injection, solution. DailyMed. 15 November 2019 [20 December 2019]. (原始內容存檔於25 November 2020). 
  21. ^ 21.00 21.01 21.02 21.03 21.04 21.05 21.06 21.07 21.08 21.09 21.10 Filgrastim. The American Society of Health-System Pharmacists. [8 December 2016]. (原始內容存檔於10 May 2017). 
  22. ^ World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. World Health Organization (WHO). 2019. hdl:10665/325771.